VAGLIO, AUGUSTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.953
AS - Asia 10.936
EU - Europa 10.011
SA - Sud America 2.300
Continente sconosciuto - Info sul continente non disponibili 460
AF - Africa 321
OC - Oceania 122
Totale 37.103
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.504
RU - Federazione Russa 3.739
IT - Italia 3.028
CN - Cina 2.920
SG - Singapore 2.797
BR - Brasile 1.842
HK - Hong Kong 1.471
VN - Vietnam 1.182
KR - Corea 1.088
IE - Irlanda 957
SE - Svezia 498
FR - Francia 436
BD - Bangladesh 399
IN - India 390
PL - Polonia 282
DE - Germania 247
CA - Canada 239
FI - Finlandia 209
AR - Argentina 185
GB - Regno Unito 152
JP - Giappone 137
ID - Indonesia 130
AU - Australia 120
NL - Olanda 95
MX - Messico 87
EC - Ecuador 77
IQ - Iraq 69
JO - Giordania 67
CH - Svizzera 63
ZA - Sudafrica 59
ES - Italia 58
CI - Costa d'Avorio 55
CO - Colombia 51
PY - Paraguay 50
UA - Ucraina 46
NG - Nigeria 41
TR - Turchia 40
AT - Austria 34
MA - Marocco 31
BE - Belgio 29
PK - Pakistan 28
BJ - Benin 26
CR - Costa Rica 26
VE - Venezuela 25
EG - Egitto 23
PE - Perù 23
CL - Cile 22
TN - Tunisia 22
BG - Bulgaria 19
JM - Giamaica 19
KE - Kenya 19
SA - Arabia Saudita 17
TH - Thailandia 17
UZ - Uzbekistan 17
AZ - Azerbaigian 16
HN - Honduras 16
IL - Israele 16
KZ - Kazakistan 15
UY - Uruguay 15
AE - Emirati Arabi Uniti 14
DO - Repubblica Dominicana 14
PH - Filippine 14
MY - Malesia 13
PT - Portogallo 12
CZ - Repubblica Ceca 11
DZ - Algeria 11
GR - Grecia 10
OM - Oman 10
TT - Trinidad e Tobago 10
HR - Croazia 9
LT - Lituania 9
NP - Nepal 9
SK - Slovacchia (Repubblica Slovacca) 9
SN - Senegal 9
AL - Albania 8
BO - Bolivia 8
GT - Guatemala 8
MK - Macedonia 8
RO - Romania 8
BH - Bahrain 7
PR - Porto Rico 7
SV - El Salvador 7
ET - Etiopia 6
IR - Iran 6
PS - Palestinian Territory 6
TW - Taiwan 6
HU - Ungheria 5
LU - Lussemburgo 5
QA - Qatar 5
AM - Armenia 4
AO - Angola 4
BY - Bielorussia 4
DK - Danimarca 4
KW - Kuwait 4
LV - Lettonia 4
SC - Seychelles 4
GE - Georgia 3
KG - Kirghizistan 3
LB - Libano 3
LI - Liechtenstein 3
Totale 36.589
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.480
Singapore 2.151
Ashburn 1.969
Hong Kong 1.243
Seoul 1.082
Hefei 1.051
Dublin 956
Fairfield 723
Milan 631
San Jose 567
Ho Chi Minh City 438
Beijing 368
Council Bluffs 338
Woodbridge 296
Chandler 292
Lawrence 282
Los Angeles 280
Altamura 275
The Dalles 273
Houston 272
Moscow 267
Warsaw 266
Seattle 265
Hanoi 264
Lauterbourg 262
Rome 261
Cambridge 229
Buffalo 227
Florence 207
Mumbai 187
Wilmington 186
Boston 180
São Paulo 169
Princeton 168
Dallas 167
New York 155
Helsinki 138
Ann Arbor 134
Kent 127
Melbourne 114
Tokyo 97
Naples 91
Paris 86
Shanghai 81
Munich 77
Chicago 72
San Diego 72
Toronto 67
Bengaluru 63
Bologna 62
Jakarta 61
Rio de Janeiro 60
Boardman 59
Da Nang 56
Figino 56
Frankfurt am Main 56
Abidjan 55
Turin 54
Orem 52
Guangzhou 50
Bern 49
Palermo 45
Chennai 43
Lappeenranta 40
Abuja 37
London 37
Phoenix 37
Brasília 36
Miano 36
Bari 34
Falls Church 34
Montreal 34
Mexico City 33
Genoa 32
Hillsboro 32
Medford 32
Atlanta 31
Redondo Beach 30
Quito 29
Haiphong 28
Biên Hòa 27
Hải Dương 27
Porto Alegre 27
Turku 27
Belo Horizonte 26
Cotonou 26
West Jordan 26
Johannesburg 25
Asunción 23
Campinas 23
Fortaleza 23
Norwalk 23
Washington 23
Brussels 22
Denver 22
Guayaquil 21
Thái Bình 21
Brescia 20
Brooklyn 20
Amsterdam 19
Totale 22.447
Salva come PNG Salva come JPEG
Nome #
Neutrophil Activation Promotes Fibrinogen Oxidation and Thrombus Formation in Behçet’s Disease 280
A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis 262
A Clinical Workflow for Cost-Saving High-Rate Diagnosis of Genetic Kidney Diseases 257
ANCA-associated vasculitis in childhood: Recent advances 253
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study 250
Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts 250
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update 245
Reverse phenotyping after whole-Exome sequencing in steroid-resistant nephrotic syndrome 241
IgG4-related disease and other fibro-inflammatory conditions 238
Brief Report: Rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Schönlein purpura) 231
IgG4-related disease: advances in pathophysiology and treatment 229
First report of FIP1L1-PDGFR alpha-positive eosinophilic granulomatosis with polyangiitis 224
A Report of 2 Cases of Kidney Involvement in ADA2 Deficiency: Different Disease Phenotypes and the Tissue Response to Type I Interferon 221
A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility 219
Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis 216
Thrombosis in vasculitis: from pathogenesis to treatment 214
Multiorgan manifestations of COL4A1 and COL4A2 variants and proposal for a clinical management protocol 209
Stem-Cell-Derived Circulating Progenitors Dysfunction in Behçet's Syndrome Patients Correlates With Oxidative Stress 201
Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19) 197
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis 195
The rise of complement in ANCA-associated vasculitis: from marginal player to target of modern therapy 194
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study 192
Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): Prospective evaluation at a tertiary referral centre 192
Fibrocytes in Chronic Periaortitis: A Novel Mechanism Linking Inflammation and Fibrosis 190
Fcγ-receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis 189
Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome: A Retrospective Study of Seventy Patients With Vascular Involvement 189
P1813CLINICAL CHARACTERIZATION OF CONGENITAL SOLITARY FUNCTIONING KIDNEY IN CHILDREN 185
OP0148 MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A RETROSPECTIVE REAL-WORLD EUROPEAN STUDY ON 142 PATIENTS 185
Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis 183
Clinical and Prognostic Significance of Serum IgG4 in Chronic Periaortitis. An Analysis of 113 Patients 182
Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management 181
Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis 181
Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status 178
Prognostic Factors and Long-Term Outcome with ANCA-Associated Kidney Vasculitis in Childhood 177
Asbestos and Smoking as Risk Factors for Idiopathic Retroperitoneal Fibrosis 175
135. ATHERO-THROMBOTIC AND VENOUS EVENTS (AVTE) IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A MULTICENTRE STUDY OF 573 ITALIAN PATIENTS 175
EBV-Associated Leukoencephalopathy with Late Onset of Central Nervous System Lymphoma in a Kidney Transplant Recipient 174
Significance of PR3-ANCA Positivity in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss) 173
Type I interferon-related kidney disorders 170
298. RITUXIMAB FOR DIFFICULT-TO-TREAT CHRONIC PARIAORTITIS: A CASE-SERIES OF 20 PATIENTS 168
Eosinophilic granulomatosis with polyangiitis: Understanding the disease and its management 167
Rituximab for chronic periaortitis without evidence of IgG4-related disease: A long-term follow-up study of 20 patients 167
At the Heart of Eosinophilic Granulomatosis with Polyangiitis: into Cardiac and Vascular Involvement 166
Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study 166
Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: A new overlap syndrome 164
Kidney involvement in Rosai-Dorfman disease 163
Gut Microbiota and Associated Mucosal Immune Response in Eosinophilic Granulomatosis with Polyangiitis (EGPA) 163
Lupus Nephritis Patterns and Response to Type I Interferon in Patients With DNASE1L3 Variants: Report of Three Cases 163
Adult-onset IgA vasculitis (Henoch-Schönlein): Update on therapy 163
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis 162
Clinical phenotypes and long-term outcome of kidney involvement in Erdheim-Chester histiocytosis 162
Association of a polymorphism of the Fcγ-receptor 2A (FCGR2A) gene with chronic periaortitis 161
Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) 161
Rare Onset of Erdheim-Chester Disease in Children and Young Adults: A Case Series and Review of the Literature 160
Erdheim–Chester disease: a rapidly evolving disease model 160
The Role of Rituximab in Primary Focal Segmental Glomerular Sclerosis of the Adult 159
Cluster Analysis to Explore Clinical Subphenotypes of Eosinophilic Granulomatosis With Polyangiitis 156
Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: Report from the European EGPA study group 155
Slowly progressive ANCA-associated renal vasculitis. Clinico-pathological characterisation and outcome 153
Persistent Isolated C3 Hypocomplementemia as a Strong Predictor of End-Stage Kidney Disease in Lupus Nephritis 152
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes 152
Cluster Analysis To Explore Clinical Subphenotypes Of Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) 151
Data-driven subclassification of ANCA-associated vasculitis: model-based clustering of a federated international cohort 151
Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis 149
New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group 149
Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study 148
A TNFSF13B Functional Variant Is Not Involved in Systemic Sclerosis and Giant Cell Arteritis Susceptibility 148
Occupational Exposures and Smoking in Eosinophilic Granulomatosis With Polyangiitis: A Case–Control Study 148
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis 147
Sirolimus plus prednisone for Erdheim-Chester disease: An open-label trial 147
Idiopathic retroperitoneal fibrosis: an update for nephrologists 147
Neutrophil Extracellular Traps in the Autoimmunity Context 147
Long-term outcome and prognosis of mixed histiocytosis (Erdheim-Chester disease and Langerhans Cell Histiocytosis) 146
The Sound of Interconnectivity; The European Vasculitis Society 2022 Report 146
Correction: Prognostic Factors and Long-Term Outcome with ANCA-Associated Kidney Vasculitis in Childhood 145
CKD therapy to improve outcomes of immune-mediated glomerular diseases 143
Long-term disease control in granulomatosis with polyangiitis: Is low-dose rituximab the cure? 142
IgG4-related disease: a contemporary review 142
[Idiopathic retroperitoneal fibrosis]. FT La fibrosi retroperitoneale idiopatica 140
Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study 140
Idiopathic Mediastinal Fibrosis: a Systemic Immune-Mediated Disorder. A Case Series and a Review of the Literature 140
Long-term follow-up of mTOR inhibition for erdheim-chester disease 140
Childhood-onset Erdheim-Chester Disease in the molecular era: clinical phenotype and long-term outcome of 21 patients 140
The emerging concept of ANCA-associated vasculitis related to inborn errors of immunity 139
Jagged Ends on Multinucleosomal Cell-Free DNA Serve as a Biomarker for Nuclease Activity and Systemic Lupus Erythematosus 139
Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis? 139
Rituximab therapy for chronic periaortitis 139
Anca testing: where are we now? 139
[18F]-Fluorodeoxyglucose Positron Emission Tomography and Response to Therapy in Idiopathic Retroperitoneal Fibrosis 139
A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis 138
Chronic periaortitis: A clinical approach 137
Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study 137
SARS-CoV-2 infection among patients with systemic autoimmune diseases 136
Microarray evaluation of allergen-specific IgE in eosinophilic granulomatosis with polyangiitis 136
F-18-fluorodeoxyglucose positron emission tomography in the diagnosis and followup of idiopathic retroperitoneal fibrosis 133
Kidney involvement in medium- and large-vessel vasculitis 130
Erdheim-Chester disease: Consensus recommendations for evaluation, diagnosis, and treatment in the molecular era 130
Aortitis and periaortitis: The puzzling spectrum of inflammatory aortic diseases 130
Chronic periaortitis: a large-vessel vasculitis? 130
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis 130
Totale 17.137
Salva come PNG Salva come JPEG
Categoria #
all - tutte 119.843
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 119.843
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.019 0 21 100 37 26 140 11 88 67 84 101 344
2022/20232.999 258 725 163 188 83 576 464 121 216 30 78 97
2023/20241.532 40 78 282 82 86 235 78 293 42 183 77 56
2024/20259.957 384 1.108 586 1.457 2.218 935 357 429 767 420 490 806
2025/202617.826 1.516 2.445 2.309 2.447 1.359 477 1.682 848 917 874 700 2.252
2026/20271.196 779 417 0 0 0 0 0 0 0 0 0 0
Totale 37.103